Cemiplimab in the treatment of cutaneous squamous cell carcinoma
- Author(s)
- McLean, LS; Lim, AM; Rischin, D;
- Details
- Publication Year 2025-12,Volume 17,Issue #17-18,Page 1249-1262
- Journal Title
- Immunotherapy
- Publication Type
- Review
- Abstract
- Immune checkpoint inhibitors (ICIs) have significantly transformed the treatment landscape of cutaneous squamous cell carcinoma (CSCC). Cemiplimab, a human IgG4 monoclonal antibody to the programmed death-1 (PD-1) receptor, has shown impressive response rates and durable disease control in patients with advanced CSCC, alongside a manageable safety profile. More recently, cemiplimab has demonstrated promising efficacy in both the adjuvant and neoadjuvant settings, with impressive improvements in disease-free survival and pathological response rates. This review provides a comprehensive overview of the current role of cemiplimab in the management of CSCC, highlighting key clinical trial data and real-world evidence on its efficacy and safety.
- Publisher
- Taylor & Francis
- Keywords
- Humans; *Antibodies, Monoclonal, Humanized/therapeutic use; *Carcinoma, Squamous Cell/drug therapy/immunology; *Skin Neoplasms/drug therapy/immunology; *Immune Checkpoint Inhibitors/therapeutic use; Programmed Cell Death 1 Receptor/antagonists & inhibitors/immunology; *Antineoplastic Agents, Immunological/therapeutic use; Cemiplimab; adjuvant; cutaneous squamous cell carcinoma; immune checkpoints; immunotherapy; metastatic; neoadjuvant
- Department(s)
- Medical Oncology
- Publisher's Version
- https://doi.org/10.1080/1750743x.2026.2619658
- Open Access at Publisher's Site
https://doi.org/10.1080/1750743x.2026.2619658- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2026-02-03 06:11:41
Last Modified: 2026-06-11 11:53:16